Capricor Therapeutics - CAPR Stock Forecast, Price & News

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

Capricor Therapeutics Price Performance

CAPR traded down $0.28 during trading on Friday, reaching $5.00. 210,690 shares of the company were exchanged, compared to its average volume of 131,140. The firm has a 50 day moving average of $4.29 and a 200 day moving average of $3.99. Capricor Therapeutics has a 52 week low of $2.56 and a 52 week high of $5.85.

Capricor Therapeutics (NASDAQ:CAPR - Get Rating) last announced its earnings results on Wednesday, August 10th. The biotechnology company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.04). During the same quarter last year, the company earned ($0.21) earnings per share. On average, research analysts forecast that Capricor Therapeutics will post -1.17 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, StockNews.com raised shares of Capricor Therapeutics to a "sell" rating in a report on Monday, May 23rd.

Insider Activity

In other Capricor Therapeutics news, Director David B. Musket sold 28,215 shares of the business's stock in a transaction that occurred on Wednesday, June 29th. The shares were sold at an average price of $3.77, for a total value of $106,370.55. Following the completion of the sale, the director now directly owns 12,747 shares of the company's stock, valued at $48,056.19. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, Director David B. Musket sold 28,215 shares of Capricor Therapeutics stock in a transaction on Wednesday, June 29th. The shares were sold at an average price of $3.77, for a total value of $106,370.55. Following the transaction, the director now owns 12,747 shares in the company, valued at approximately $48,056.19. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director David B. Musket sold 17,775 shares of Capricor Therapeutics stock in a transaction dated Monday, June 27th. The stock was sold at an average price of $4.44, for a total value of $78,921.00. Following the completion of the transaction, the director now owns 40,962 shares in the company, valued at $181,871.28. The disclosure for this sale can be found here. 9.00% of the stock is currently owned by corporate insiders.